UMIN-ICDS History

Name：　　UMIN ID：

Unique ID issued by UMIN	UMIN000062648
Receipt number	R000071333
Scientific Title	Phase I/II study evaluating the safety, tolerability, and efficacy of sacituzumab govitecan administered on day 1 and day 8 in combination with pegfilgrastim on day 2 in patients with unresectable or recurrent HER2-negative breast cancer
Date of disclosure of the study information	2026/08/21
Last modified on	2026/08/21 16:48:37

---